Search

Displaying results 2751 - 2760 of 10000 in total
  1. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    a greater affinity for free serum IgE and an altered sensitivity to IgE conformation. … Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer

  2. Drug

    Stepronin

    go.drugbank.com/drugs/DB01423
    Experimental

    Strepronin is a mucolytic drug. A mucolytic agent is any agent which dissolves thick mucus usually used to help relieve respiratory difficulties. … The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucoprotein as well as the presence of disulfide bonds between these macromolecules and DNA.

  3. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  4. Drug

    Streptokinase

    go.drugbank.com/drugs/DB00086
    ApprovedInvestigationalWithdrawn

    Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci.

  5. Drug

    Spiramycin

    go.drugbank.com/drugs/DB06145
    ApprovedInvestigationalWithdrawn

    Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. … Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types

    Synonyms: Foromacidin A, Spiramycin A
  6. Drug

    Econazole

    go.drugbank.com/drugs/DB01127
    Approved

    A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.

  7. Drug

    Desflurane

    go.drugbank.com/drugs/DB01189
    ApprovedInvestigational

    Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane]. … It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]

  8. Drug

    Acetyl sulfisoxazole

    go.drugbank.com/drugs/DB14033
    ApprovedVet approved

    Sulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity. … This process causes an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, resulting in cell growth arrest and cell death [L2788].

  9. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. … Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative

  10. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors. … Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing.